Should I buy or sell SpringWorks Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWTX shares. View SWTX analyst ratings or view top-rated stocks .

What is SpringWorks Therapeutics' stock price target for 2024?

6 Wall Street analysts have issued 12-month price objectives for SpringWorks Therapeutics' stock. Their SWTX share price targets range from $52.00 to $75.00. On average, they predict the company's share price to reach $68.00 in the next year. This suggests a possible upside of 54.2% from the stock's current price. View analysts price targets for SWTX or view top-rated stocks among Wall Street analysts .

How have SWTX shares performed in 2024?

SpringWorks Therapeutics' stock was trading at $36.50 at the start of the year. Since then, SWTX shares have increased by 20.8% and is now trading at $44.11. View the best growth stocks for 2024 here .

When is SpringWorks Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our SWTX earnings forecast .

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) announced its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.44) earnings per share for the quarter, missing analysts' consensus estimates of ($1.24) by $0.20. The firm had revenue of $5.45 million for the quarter, compared to analyst estimates of $1.26 million. During the same quarter last year, the firm earned ($1.19) earnings per share.

What ETFs hold SpringWorks Therapeutics' stock?

ETFs with the largest weight of SpringWorks Therapeutics (NASDAQ:SWTX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) , Virtus LifeSci Biotech Products ETF (BBP) , ALPS Medical Breakthroughs ETF (SBIO) and First Trust Innovation Leaders ETF (ILDR) . Invesco Dorsey Wright Healthcare Momentum ETF (PTH) .

What other stocks do shareholders of SpringWorks Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM) , Dicerna Pharmaceuticals (DRNA) , Johnson & Johnson (JNJ) , Albireo Pharma (ALBO) , Gilead Sciences (GILD) , Sunrun (RUN) , Alnylam Pharmaceuticals (ALNY) , Aptevo Therapeutics (APVO) , Bristol-Myers Squibb (BMY) and BioXcel Therapeutics (BTAI) .

When did SpringWorks Therapeutics IPO?

SpringWorks Therapeutics (SWTX) raised $126 million in an IPO on Friday, September 13th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are SpringWorks Therapeutics' major shareholders?

SpringWorks Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.05%) and Los Angeles Capital Management LLC (0.02%). Insiders that own company stock include Badreddin Edris , Bain Capital Life Sciences Inv, Daniel Pichl , Julie Hambleton , L Mary Smith , Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto . View institutional ownership trends .

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does SpringWorks Therapeutics have any subsidiaries?

The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc.. Read More

NASDAQ:SWTX

SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis

→ Don’t expose yourself to stocks during the week (From DTI) (Ad)

Free SWTX Stock Alerts

$44.11

+0.71 (+1.64%)

(As of 04/17/2024 ET)

Compare

Today's Range: $43.43
▼
$44.62
50-Day Range: $42.51
▼
$52.50
52-Week Range: $18.00
▼
$53.92

Volume: 841,170 shs
Average Volume: 643,586 shs
Market Capitalization: $3.25 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $68.00

Get SpringWorks Therapeutics alerts:

SpringWorks Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 54.2% Upside
$68.00 Price Target
Short Interest: Bearish
14.45% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.01
Based on 3 Articles This Week
Insider Trading: Selling Shares
$751,500 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.71) to ($3.27) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.58 out of 5 stars

Medical Sector

444th out of 914 stocks

Biological Products, Except Diagnostic Industry

70th out of 153 stocks

4.5

Analyst's Opinion

Consensus Rating
SpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
SpringWorks Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
14.45% of the outstanding shares of SpringWorks Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
SpringWorks Therapeutics has a short interest ratio ("days to cover") of 9.3.
Change versus previous month
Short interest in SpringWorks Therapeutics has recently decreased by 4.57%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
SpringWorks Therapeutics does not currently pay a dividend.
Dividend Growth
SpringWorks Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SWTX.

2.2

News and Social Media Coverage

News Sentiment
SpringWorks Therapeutics has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for SpringWorks Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for SWTX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SpringWorks Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $751,500.00 in company stock.
Percentage Held by Insiders
Only 7.61% of the stock of SpringWorks Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($4.71) to ($3.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SpringWorks Therapeutics is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of SpringWorks Therapeutics is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
SpringWorks Therapeutics has a P/B Ratio of 4.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

Click here and I’ll give you all the details.

About SpringWorks Therapeutics Stock (NASDAQ:SWTX)

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

SWTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SWTX Stock News Headlines

April 18, 2024 | globenewswire.com

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

April 15, 2024 | nasdaq.com

SWTX Quantitative Stock Analysis

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 17, 2024 | finance.yahoo.com

SWTX Apr 2024 70.000 call

March 13, 2024 | investorplace.com

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

March 6, 2024 | finance.yahoo.com

SWTX Apr 2024 60.000 put

March 6, 2024 | finance.yahoo.com

SWTX Apr 2024 65.000 call

March 4, 2024 | globenewswire.com

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

April 18, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

February 29, 2024 | globenewswire.com

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

February 28, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Tarsus Pharmaceuticals (TARS) and Springworks Therapeutics (SWTX)

February 27, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Telesis Bio (TBIO) and Springworks Therapeutics (SWTX)

February 27, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX) and ACADIA Pharmaceuticals (ACAD)

February 27, 2024 | finance.yahoo.com

SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results

February 27, 2024 | globenewswire.com

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

February 24, 2024 | msn.com

SpringWorks Therapeutics (SWTX) Price Target Increased by 13.30% to 62.40

February 22, 2024 | finance.yahoo.com

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

February 22, 2024 | globenewswire.com

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

February 16, 2024 | msn.com

Viking Therapeutics gains amid renewed takeover speculation

February 7, 2024 | finance.yahoo.com

SpringWorks Therapeutics Inc Insider Sells Company Shares

February 6, 2024 | finance.yahoo.com

SpringWorks Therapeutics Inc Chief People Officer Daniel Pichl Sells 26,181 Shares

February 3, 2024 | msn.com

SpringWorks Therapeutics CDO Resigns, Assumes Advisory Role

January 31, 2024 | forbes.com

Serendipity And Science: Forging Billion-Dollar Oncology Breakthroughs

January 31, 2024 | finance.yahoo.com

SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 25, 2024 | markets.businessinsider.com

Wall Street Analysts Are Bullish on Top Healthcare Picks

January 19, 2024 | benzinga.com

SpringWorks Therapeutics's Options Frenzy: What You Need to Know

January 10, 2024 | msn.com

TG Therapeutics prelim results see FY23 BRIUMVI U.S. revenue $89M; initiates FY24 outlook

See More Headlines

Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:SWTX
CUSIP: N/A
CIK: 1773427
Web: www.springworkstx.com
Phone: 203-883-9490
Fax: N/A
Employees: 305
Year Founded: 2017

Price Target and Rating

Average Stock Price Target: $68.00
High Stock Price Target: $75.00
Low Stock Price Target: $52.00
Potential Upside/Downside: +54.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-325,100,000.00
Net Margins: N/A
Pretax Margin: -5,968.50%
Return on Equity: -65.69%
Return on Assets: -57.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.41
Quick Ratio: 6.37

Sales & Book Value

Annual Sales: $5.45 million
Price / Sales: 597.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.01 per share
Price / Book: 4.41

Miscellaneous

Outstanding Shares: 73,790,000
Free Float: 68,172,000
Market Cap: $3.25 billion
Optionable: Optionable
Beta: 0.83

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Saqib Islam J.D. (Age 54)
CEO & Director
Comp: $1.26M
Mr. Francis I. Perier Jr. (Age 64)
M.B.A., Chief Financial Officer
Comp: $710.6k
Dr. Badreddin Edris Ph.D. (Age 36)
Chief Operating Officer
Comp: $998.61k
Mr. Bhavesh Ashar (Age 57)
Chief Commercial Officer
Comp: $729.62k
Mr. Michael P. Nofi (Age 53)
Chief Accounting Officer
Mr. Tai-An Lin Ph.D.
Chief Scientific Officer
Ms. Kim Diamond
Vice President of Communications & Investor Relations
Mr. Herschel S. Weinstein J.D. (Age 67)
General Counsel & Secretary
Comp: $568.64k
Mr. Daniel J. Pichl (Age 40)
Chief People Officer
Comp: $428.51k
Dr. James Cassidy M.D. (Age 64)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SWTX Stock Analysis - Frequently Asked Questions

Should I buy or sell SpringWorks Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWTX shares.
View SWTX analyst ratings or view top-rated stocks.
What is SpringWorks Therapeutics' stock price target for 2024?: 6 Wall Street analysts have issued 12-month price objectives for SpringWorks Therapeutics' stock. Their SWTX share price targets range from $52.00 to $75.00. On average, they predict the company's share price to reach $68.00 in the next year. This suggests a possible upside of 54.2% from the stock's current price.
View analysts price targets for SWTX or view top-rated stocks among Wall Street analysts.
How have SWTX shares performed in 2024?: SpringWorks Therapeutics' stock was trading at $36.50 at the start of the year. Since then, SWTX shares have increased by 20.8% and is now trading at $44.11.
View the best growth stocks for 2024 here.
When is SpringWorks Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our SWTX earnings forecast.
How were SpringWorks Therapeutics' earnings last quarter?: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) announced its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.44) earnings per share for the quarter, missing analysts' consensus estimates of ($1.24) by $0.20. The firm had revenue of $5.45 million for the quarter, compared to analyst estimates of $1.26 million. During the same quarter last year, the firm earned ($1.19) earnings per share.
What ETFs hold SpringWorks Therapeutics' stock?: ETFs with the largest weight of SpringWorks Therapeutics (NASDAQ:SWTX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO) and First Trust Innovation Leaders ETF (ILDR).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

What other stocks do shareholders of SpringWorks Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN), Alnylam Pharmaceuticals (ALNY), Aptevo Therapeutics (APVO), Bristol-Myers Squibb (BMY) and BioXcel Therapeutics (BTAI).
When did SpringWorks Therapeutics IPO?: SpringWorks Therapeutics (SWTX) raised $126 million in an IPO on Friday, September 13th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are SpringWorks Therapeutics' major shareholders?: SpringWorks Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.05%) and Los Angeles Capital Management LLC (0.02%). Insiders that own company stock include Badreddin Edris, Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith, Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto.
View institutional ownership trends.
How do I buy shares of SpringWorks Therapeutics?: Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does SpringWorks Therapeutics have any subsidiaries?: The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..
Read More

This page (NASDAQ:SWTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial